Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy

被引:36
作者
Bowring, Mary G. [1 ]
Kucirka, Lauren M. [1 ,2 ]
Massie, Allan B. [1 ,2 ]
Ishaque, Tanveen [1 ]
Bae, Sunjae [1 ]
Shaffer, Ashton A. [1 ,2 ]
Wang, Jacqueline Garonzik [1 ]
Sulkowski, Mark [3 ]
Desai, Niraj [3 ]
Segev, Dorry L. [1 ,2 ,4 ]
Durand, Christine M. [3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[4] Sci Registry Transplant Recipients, Minneapolis, MN USA
关键词
HEPATITIS-C VIRUS; TRANSPLANT RECIPIENTS; RENAL-TRANSPLANTATION; ALLOGRAFT-REJECTION; SURVIVAL BENEFIT; GENOTYPE; HEMODIALYSIS; INFECTION; IMPACT; DISEASE;
D O I
10.1097/TP.0000000000002323
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The availability of direct-acting antiviral (DAA) therapy might have impacted use of hepatitis C virus (HCV)-infected (HCV+) deceased donor kidneys for transplantation. Methods. We used 2005 to 2018 Scientific Registry of Transplant Recipients data to identify 18936 candidates willing to accept HCV+ kidneys and 3348 HCV+ recipients of HCV+ kidneys. We compared willingness to accept, utilization, discard, and posttransplant outcomes associated with HCV+ kidneys between 2 treatment eras (interferon [IFN] era, January 1, 2005 to December 5, 2013 vs DAA era, December 6, 2013 to August 2, 2018). Models were adjusted for candidate, recipient, and donor factors where appropriate. Results. In the DAA era, candidates were 2.2 times more likely to list as willing to accept HCV+ kidneys (adjusted odds ratio, (2.07)2.23(2.41); P < 0.001), and HCV+ recipients were 1.95 times more likely to have received an HCV+ kidney (adjusted odds ratio, (1.76)1.95(2.16); P < 0.001). Median Kidney Donor Profile Index of HCV+ kidneys decreased from 77 (interquartile range [IQR], 59-90) in 2005 to 53 (IQR, 40-67) in 2017. Kidney Donor Profile Index of HCV-kidneys remained unchanged from 45 (IQR, 21-74) to 47 (IQR, 24-73). After adjustment, HCV+ kidneys were 3.7 times more likely to be discarded than HCV-kidneys in the DAA era (adjusted relative rate, (3.36)3.67(4.02); P < 0.001); an increase from the IFN era (adjusted relative rate, (2.78)3.02(3.27); P < 0.001). HCV+ kidney use was concentrated within a subset of centers; 22.5% of centers performed 75% of all HCV+ kidney transplants in the DAA era. Mortality risk associated with HCV+ kidneys remained unchanged (aHR, (1.07)1.19(1.32) in both eras). Conclusions. Given the elevated risk of death on dialysis facing HCV+ candidates, improving quality of HCV+ kidneys, and DAA availability, broader utilization of HCV+ kidneys is warranted to improve access in this era of organ shortage.
引用
收藏
页码:2088 / 2095
页数:8
相关论文
共 51 条
[1]   The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients [J].
Abbott, KC ;
Lentine, KL ;
Bucci, JR ;
Agodoa, LY ;
Peters, TG ;
Schnitzler, MA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (12) :2032-2037
[2]  
[Anonymous], Recommendations for testing, managing, and treating hepatitis C
[3]  
Axelrod DA, 2018, AM J TRANSPLANT
[4]   Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list [J].
Bloom, RD ;
Sayer, G ;
Fa, K ;
Constantinescu, S ;
Abt, P ;
Reddy, KR .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (01) :139-144
[5]   Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era [J].
Bowring, M. G. ;
Kucirka, L. M. ;
Massie, A. B. ;
Luo, X. ;
Cameron, A. ;
Sulkowski, M. ;
Rakestraw, K. ;
Gurakar, A. ;
Kuo, I. ;
Segev, D. L. ;
Durand, C. M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (02) :519-527
[6]   Turn down for what? Patient outcomes associated with declining increased infectious risk kidneys [J].
Bowring, Mary G. ;
Holscher, Courtenay M. ;
Zhou, Sheng ;
Massie, Allan B. ;
Garonzik-Wang, Jacqueline ;
Kucirka, Lauren M. ;
Gentry, Sommer E. ;
Segev, Dorry L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (03) :617-624
[7]   Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis [J].
Butt, A. A. ;
Skanderson, M. ;
McGinnis, K. A. ;
Ahuja, T. ;
Bryce, C. L. ;
Barnato, A. E. ;
Chang, C.-C. H. .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (10) :688-696
[8]   Acute renal allograft rejection following pegylated IFN-α treatment for chronic HCV in a repeat allograft recipient on hemodialysis:: A case report [J].
Carbognin, S. J. ;
Solomon, N. M. ;
Yeo, F. E. ;
Swanson, S. J. ;
Bohen, E. M. ;
Koff, J. M. ;
Sabnis, S. G. ;
Abbott, K. C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (07) :1746-1751
[9]   Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection A PRISMA-compliant study [J].
Chen, Keliang ;
Lu, Pei ;
Song, Rijin ;
Zhang, Jiexiu ;
Tao, Rongzhen ;
Wang, Zijie ;
Zhang, Wei ;
Gu, Min .
MEDICINE, 2017, 96 (30)
[10]   Kidney Transplantation Threshold in Patients With Hepatitis C: A Decision Analysis Model [J].
Choi, Gina ;
Lee, Kristina G. ;
Wu, Crystal ;
Saab, Sammy .
TRANSPLANTATION, 2015, 99 (04) :829-834